Statement Of Cash Flows [Abstract]

Zealand Pharma - Filing #5889383

Concept 2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
As at
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
1,078,828,000 DKK
- DKK
- DKK
- DKK
1,078,828,000 DKK
- DKK
703,739,000 DKK
- DKK
703,739,000 DKK
- DKK
Adjustments to reconcile profit (loss) [abstract]
Other adjustments for non-cash items
80,501,000 DKK
202,033,000 DKK
Cash flows from (used in) operating activities
930,816,000 DKK
425,668,000 DKK
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, classified as investing activities
10,053,000 DKK
11,241,000 DKK
Purchase of intangible assets, classified as investing activities
3,095,000 DKK
12,508,000 DKK
Cash flows from (used in) investing activities
7,332,915,000 DKK
1,094,033,000 DKK
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
8,492,752,000 DKK
1,500,000,000 DKK
Payments to acquire or redeem entity's shares
351,834,000 DKK
41,600,000 DKK
Proceeds from borrowings, classified as financing activities
369,867,000 DKK
- DKK
Repayments of borrowings, classified as financing activities
- DKK
525,764,000 DKK
Payments of lease liabilities, classified as financing activities
16,442,000 DKK
17,664,000 DKK
Cash flows from (used in) financing activities
8,288,491,000 DKK
907,014,000 DKK
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
24,760,000 DKK
612,687,000 DKK
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
6,232,000 DKK
7,236,000 DKK
Cash and cash equivalents
480,303,000 DKK
449,311,000 DKK
1,069,234,000 DKK

Talk to a Data Expert

Have a question? We'll get back to you promptly.